{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024270","form_type":"8-K","ticker":"CNTN","cik":"0001861657","company_name":"Canton Strategic Holdings, Inc.","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.862620+00:00","generated_at":"2026-06-13T10:16:11.984743+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Hillstream BioPharma signs ABSI license for ErbB2/ErbB3; appoints Sireesh Appajosyula as COO","bullets":["Licensed exclusive rights from ABSI to develop antibodies targeting ErbB2 (Her2) and ErbB3 in all human/animal diseases worldwide.","Will issue $250k in common stock to ABSI within 30 days; milestones up to $8.25M; royalties low-to-mid single digits on net sales.","Appointed director Sireesh Appajosyula as COO effective July 6, 2023; base salary $400k, annual bonus target 50% of base.","Amended CEO Randy Milby's employment: base $500k, bonus target 60%, severance period increased to 18 months on certain terminations."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024270","json":"https://secwatch.observer/filing/0001493152-23-024270.json","markdown":"https://secwatch.observer/filing/0001493152-23-024270.md","text":"https://secwatch.observer/filing/0001493152-23-024270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/0001493152-23-024270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:16:11.984743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7241ebf45a","claim":"Sireesh Appajosyula was appointed as Chief Operating Officer at Canton Strategic Holdings, Inc..","evidence_excerpt":"On July 6, 2023, the Board appointed Sireesh Appajosyula, the Company’s director, as Chief Operating Officer of the Company effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/0001493152-23-024270-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"b6b22031cef5c1cbfd85a5d8c3f15cc9c4108a27","claim":"Canton Strategic Holdings, Inc. entered into ABSI Agreement with Applied Biomedical Science Institute (ABSI) valued at $250,000 (effective 2023-07-05).","evidence_excerpt":"On July 5, 2023 (the “ABSI Effective Date”), Hillstream BioPharma, Inc. (the “Company”) entered into a Research and Development Collaboration and License Agreement (the “ABSI Agreement”) with Applied Biomedical Science Institute (“ABSI”) pursuant to which ABSI granted the Company an exclusive royalty-bearing, sublicensable license to the ABSI Patents","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/0001493152-23-024270-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Applied Biomedical Science Institute (ABSI)"},{"label":"Value","value":"$250,000"},{"label":"Effective","value":"2023-07-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}